Brainstorm Cell Therapeutics logo

Brainstorm Cell Therapeutics share price today

(BCLI)

Brainstorm Cell Therapeutics share price is $2.23 & ₹189.99 as on 25 Dec 2024, 2.30 'hrs' IST

$2.23

0.16

(7.73%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Brainstorm Cell Therapeutics share price in Dollar and Rupees. Guide to invest in Brainstorm Cell Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Brainstorm Cell Therapeutics. Get details on the Indian mutual funds that are investing in Brainstorm Cell Therapeutics. Get Analyst recommendations and forecasts along with all the Brainstorm Cell Therapeutics's financials.

Brainstorm Cell Therapeutics share price movements

  • Today's Low: $2.10
    Today's High: $2.23

    Day's Volatility :5.83%

  • 52 Weeks Low: $1.05
    52 Weeks High: $11.89

    52 Weeks Volatility :91.17%

Brainstorm Cell Therapeutics Returns

PeriodBrainstorm Cell Therapeutics IncIndex (Russel 2000)
3 Months
-41.58%
0.0%
6 Months
-58.75%
0.0%
1 Year
-48.02%
0.0%
3 Years
-96.01%
-21.1%

Brainstorm Cell Therapeutics Key Statistics

in dollars & INR

Previous Close
$2.07
Open
$2.09
Today's High
$2.23
Today's Low
$2.1
Market Capitalization
$12.7M
Today's Volume
$59.1K
52 Week High
$11.8905
52 Week Low
$1.05
Revenue TTM
$0.0
EBITDA
$-16.0M
Earnings Per Share (EPS)
$-3.45
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-1121.9%

How to invest in Brainstorm Cell Therapeutics from India?

It is very easy for Indian residents to invest directly in Brainstorm Cell Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Brainstorm Cell Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Brainstorm Cell Therapeutics or BCLI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Brainstorm Cell Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Brainstorm Cell Therapeutics shares which would translate to 0.382 fractional shares of Brainstorm Cell Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Brainstorm Cell Therapeutics, in just a few clicks!

Returns in Brainstorm Cell Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Brainstorm Cell Therapeutics investment value today

Current value as on today

₹54,220

Returns

₹45,780

(-45.78%)

Returns from Brainstorm Cell Therapeutics Stock

₹48,019 (-48.02%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Brainstorm Cell Therapeutics

36%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Brainstorm Cell Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 36% more investors are searching Brainstorm Cell Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Brainstorm Cell Therapeutics

  • Armistice Capital, LLC

    9.25%

  • Vanguard Group Inc

    1.77%

  • Geode Capital Management, LLC

    0.57%

  • BlackRock Inc

    0.45%

  • Liberty Wealth Management, LLC

    0.40%

  • Weaver Consulting Group

    0.27%

Analyst Recommendation on Brainstorm Cell Therapeutics

Sell

    0%Buy

    50%Hold

    50%Sell

Based on 6 Wall street analysts offering stock ratings for Brainstorm Cell Therapeutics(by analysts ranked 0 to 5 stars)

Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
0
0
0
Hold
3
3
3
Sell
3
3
3

Analyst Forecast on Brainstorm Cell Therapeutics

What analysts predicted

Upside of 951.57%

Current:

$2.23

Target:

$23.45

Insights on Brainstorm Cell Therapeutics

  • Price Movement

    In the last 1 month, BCLI stock has moved up by 37.7%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, -569.0K → 365.0K (in $), with an average increase of 255.9% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -2.54M → -2.70M (in $), with an average decrease of 6.6% per quarter
  • BCLI vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 62.6%
  • BCLI vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 121.2%

Brainstorm Cell Therapeutics Technicals Summary

Sell

Neutral

Buy

Brainstorm Cell Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Brainstorm Cell Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Brainstorm Cell Therapeutics Inc
37.65%
-58.75%
-48.02%
-96.01%
-96.53%
Regeneron Pharmaceuticals, Inc.
-5.12%
-32.01%
-18.29%
12.56%
91.19%
Biontech Se
-3.72%
41.99%
6.11%
-55.22%
226.93%
Alnylam Pharmaceuticals, Inc.
-3.99%
-1.52%
23.75%
50.98%
112.09%
Vertex Pharmaceuticals Incorporated
-12.61%
-13.61%
0.03%
83.58%
86.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Brainstorm Cell Therapeutics Inc
NA
NA
0.0
-2.1
-11.22
-1.78
NA
-1.2
Regeneron Pharmaceuticals, Inc.
17.67
17.67
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Brainstorm Cell Therapeutics Inc
Sell
$12.7M
-96.53%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.5B
91.19%
17.67
33.61%
Biontech Se
Buy
$27.4B
226.93%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$31.4B
112.09%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$105.1B
86.41%
32.84
-4.51%

About Brainstorm Cell Therapeutics

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Organization
Brainstorm Cell Therapeutics
Employees
29
CEO
Mr. Chaim Lebovits
Industry
Electronic Technology

Management People of Brainstorm Cell Therapeutics

NameTitle
Mr. Chaim Lebovits
President & CEO
Dr. Irit Arbel DSc, Ph.D.
Co-Founder & Independent Vice Chair of the Board
Ms. Alla Patlis CPA, M.B.A.
Interim CFO & Controller
Mr. Uri Yablonka
Executive VP, Chief Business Officer, Secretary & Director
Dr. Hartoun Hartounian Ph.D.
Executive VP & COO
Dr. Daniel Offen Ph.D.
Chief Scientific Advisor
Ms. Mary Kay Turner
Senior Vice President of Patient Advocacy & Government Affairs
Dr. Ibrahim Dagher M.D.
Executive VP & Chief Medical Officer
Dr. Netta Blondheim-Shraga Ph.D.
Senior Vice President of Research and Development

Important FAQs about investing in Brainstorm Cell Therapeutics from India :

What is Brainstorm Cell Therapeutics share price today?

Brainstorm Cell Therapeutics share price today stands at $2.23, Open: $2.09 ; Previous Close: $2.07 ; High: $2.23 ; Low: $2.10 ; 52 Week High: $11.89 ; 52 Week Low: $1.05. The stock opens at $2.09, after a previous close of $2.07. The stock reached a daily high of $2.23 and a low of $2.10, with a 52-week high of $11.89 and a 52-week low of $1.05.

Can Indians buy Brainstorm Cell Therapeutics shares?

Yes, Indians can invest in the Brainstorm Cell Therapeutics (BCLI) from India.

With INDmoney, you can buy Brainstorm Cell Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Brainstorm Cell Therapeutics at zero transaction cost.

How can I buy Brainstorm Cell Therapeutics shares from India?

It is very easy to buy Brainstorm Cell Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Brainstorm Cell Therapeutics be purchased?

Yes, you can buy fractional shares of Brainstorm Cell Therapeutics with INDmoney app.

What are the documents required to start investing in Brainstorm Cell Therapeutics stocks?

To start investing in Brainstorm Cell Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Brainstorm Cell Therapeutics

Today’s highest price of Brainstorm Cell Therapeutics (BCLI) is $2.23.

Today’s lowest price of Brainstorm Cell Therapeutics (BCLI) is $2.10.

What is today's market capitalisation of Brainstorm Cell Therapeutics

Today's market capitalisation of Brainstorm Cell Therapeutics BCLI is 12.7M

What is the 52 Week High and Low Range of Brainstorm Cell Therapeutics

  • 52 Week High

    $11.89

  • 52 Week Low

    $1.05

What are the historical returns of Brainstorm Cell Therapeutics?

  • 1 Month Returns

    37.65%

  • 3 Months Returns

    -58.75%

  • 1 Year Returns

    -48.02%

  • 5 Years Returns

    -96.53%

Who is the Chief Executive Officer (CEO) of Brainstorm Cell Therapeutics

Mr. Chaim Lebovits is the current Chief Executive Officer (CEO) of Brainstorm Cell Therapeutics.